NeoGenomics Announces Participation in NCI-MATCH Clinical Trial
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: GlobeNewswire
FT. MYERS, Fla., Sept. 24, 2018 (GLOBE NEWSWIRE) -- NeoGenomics Laboratories, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine cancer treatment clinical trial. In NCI-MATCH, patients are assigned to receive treatment based on gene changes found in their tumors. The trial is being co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The goal of NCI-MATCH is to determine the effectiveness of treating patients based on specific tumor gene changes, independent of cancer type. Designated gene sequencing laboratories such as NeoGenomics identify potentially eligible patients being treated at clinical sites participating in the NCI-MATCH trial, through genomic testing. Such testing is performed at the request
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics announces senior leadership promotions [Seeking Alpha]Seeking Alpha
- NeoGenomics Announces Senior Leadership Promotions [Yahoo! Finance]Yahoo! Finance
- NeoGenomics Announces Senior Leadership PromotionsBusiness Wire
- NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024Business Wire
- NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 2/20/24 - Beat
NEO
Sec Filings
- 4/18/24 - Form 8-K
- 4/8/24 - Form ARS
- 4/8/24 - Form DEFA14A
- NEO's page on the SEC website